Literature DB >> 33466745

Synergism of Proneurogenic miRNAs Provides a More Effective Strategy to Target Glioma Stem Cells.

Adam Kosti1,2, Rodrigo Barreiro1,3,4, Gabriela D A Guardia3, Shiva Ostadrahimi1, Erzsebet Kokovay2, Alexander Pertsemlidis1,5, Pedro A F Galante3,4, Luiz O F Penalva1,2.   

Abstract

Tumor suppressor microRNAs (miRNAs) have been explored as agents to target cancer stem cells. Most strategies use a single miRNA mimic and present many disadvantages, such as the amount of reagent required and the diluted effect on target genes. miRNAs work in a cooperative fashion to regulate distinct biological processes and pathways. Therefore, we propose that miRNA combinations could provide more efficient ways to target cancer stem cells. We have previously shown that miR-124, miR-128, and miR-137 function synergistically to regulate neurogenesis. We used a combination of these three miRNAs to treat glioma stem cells and showed that this treatment was much more effective than single miRNAs in disrupting cell proliferation and survival and promoting differentiation and response to radiation. Transcriptomic analyses indicated that transcription regulation, angiogenesis, metabolism, and neuronal differentiation are among the main biological processes affected by transfection of this miRNA combination. In conclusion, we demonstrated the value of using combinations of neurogenic miRNAs to disrupt cancer phenotypes and glioma stem cell growth. The synergistic effect of these three miRNA amplified the repression of oncogenic factors and the effect on cancer relevant pathways. Future therapeutic approaches would benefit from utilizing miRNA combinations, especially when targeting cancer-initiating cell populations.

Entities:  

Keywords:  glioblastoma; miR-124; miR-128; miR-137; miRNA; neuroblastoma

Year:  2021        PMID: 33466745      PMCID: PMC7831004          DOI: 10.3390/cancers13020289

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  106 in total

1.  A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells.

Authors:  Yi Chieh Lim; Tara L Roberts; Bryan W Day; Angus Harding; Sergei Kozlov; Amanda W Kijas; Kathleen S Ensbey; David G Walker; Martin F Lavin
Journal:  Mol Cancer Ther       Date:  2012-07-06       Impact factor: 6.261

Review 2.  Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2018-11-27       Impact factor: 7.658

3.  Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.

Authors:  Yongxin Chen; Raymond L Stallings
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

4.  Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells.

Authors:  Shaheen Khan; Maen Abdelrahim; Ismael Samudio; Stephen Safe
Journal:  Endocrinology       Date:  2003-06       Impact factor: 4.736

Review 5.  MicroRNA and cancer.

Authors:  Martin D Jansson; Anders H Lund
Journal:  Mol Oncol       Date:  2012-10-09       Impact factor: 6.603

6.  miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1.

Authors:  Liqin Du; Jeoffrey J Schageman; Maria C Subauste; Barbara Saber; Scott M Hammond; Ludmila Prudkin; Ignacio I Wistuba; Lin Ji; Jack A Roth; John D Minna; Alexander Pertsemlidis
Journal:  Mol Cancer Res       Date:  2009-08-11       Impact factor: 5.852

Review 7.  ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.

Authors:  Nico Jacobi; Rita Seeboeck; Elisabeth Hofmann; Andreas Eger
Journal:  Cancers (Basel)       Date:  2017-04-12       Impact factor: 6.639

8.  Correlations of lncRNAs with cervical lymph node metastasis and prognosis of papillary thyroid carcinoma.

Authors:  Na Li; Mingming Cui; Ping Yu; Qiang Li
Journal:  Onco Targets Ther       Date:  2019-02-18       Impact factor: 4.147

9.  Potential Impact of miR-137 and Its Targets in Schizophrenia.

Authors:  Carrie Wright; Jessica A Turner; Vince D Calhoun; Nora Perrone-Bizzozero
Journal:  Front Genet       Date:  2013-04-26       Impact factor: 4.599

Review 10.  Analysis of drug combinations: current methodological landscape.

Authors:  Julie Foucquier; Mickael Guedj
Journal:  Pharmacol Res Perspect       Date:  2015-05-20
View more
  2 in total

1.  LncRNA FOXD3-AS1 Promotes Tumorigenesis of Glioma via Targeting miR-128-3p/SZRD1 Axis.

Authors:  Zhang Li; Ming Li; Pengcheng Xia; Lili Wang; Zhiming Lu
Journal:  Cancer Manag Res       Date:  2021-12-07       Impact factor: 3.989

2.  A miR-137-XIAP axis contributes to the sensitivity of TRAIL-induced cell death in glioblastoma.

Authors:  Fenghao Geng; Fen Yang; Fang Liu; Jianhui Zhao; Rui Zhang; Shijie Hu; Jie Zhang; Xiao Zhang
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.